1 / 2

Étude OLIVIA

Étude OLIVIA. Survie sans progression Tous patients. Médiane (IC 95 ). 1,0. BEV + FOLFOXIRI. 18,8 mois (12,4-21,0 ). 0,8. BEV + mFOLFOX6. 12,0 mois (9,5-14,1 ). 0,6. HR = 0,40 (0,23-0,70) p = 0,0012. Probabilité de SSP. 0,4. 0,2. 12,0. 18,8. 0. 0. 3. 6. 9. 12. 15. 18.

natalie-lara
Download Presentation

Étude OLIVIA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Étude OLIVIA Survie sans progressionTous patients Médiane (IC95) 1,0 BEV + FOLFOXIRI 18,8 mois (12,4-21,0) 0,8 BEV + mFOLFOX6 12,0 mois (9,5-14,1) 0,6 HR = 0,40 (0,23-0,70)p = 0,0012 Probabilité de SSP 0,4 0,2 12,0 18,8 0 0 3 6 9 12 15 18 21 24 27 30 33 Mois Patients à risque (n) 39 41 37 38 33 37 24 31 16 27 8 22 2 19 2 9 1 4 0 2 0 1 0 0 • ESMO 2013 - D’après Bridgewater J et al., abstr. 2159, actualisé • La Lettre du Cancérologue

  2. Étude OLIVIA Survie sans progressionPatients avec résection R0/R1 Médiane (IC95) 1,0 BEV + FOLFOXIRI 21,0 mois (16,0-31,8) 0,8 BEV + mFOLFOX6 13,6 mois (9,8-15,9) 0,6 Probabilité de SSP 0,4 0,2 13,6 21,0 0 0 3 6 9 12 15 18 21 24 27 30 33 Mois Patients à risque (n) 13 21 13 21 13 21 11 19 8 18 3 15 1 13 1 7 0 4 0 2 0 1 0 0 • ESMO 2013 - D’après Bridgewater J et al., abstr. 2159, actualisé • La Lettre du Cancérologue

More Related